Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2022 - 03 - 28 save search
Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes
Published: 2022-03-28 (Crawled : 23:00) - prnewswire.com
NVO | $123.9 -0.49% 0.23% 2.9M
|
Health Technology
|
| O: 2.86%
H: 0.47%
C: -0.72%
ozempic fda control approval diabetes
Monarch Mining Corporation Receives Shareholder Approval by Written Resolution for Private Placement
Published: 2022-03-28 (Crawled : 22:00) - globenewswire.com
AGI | $14.99 -1.45% 0.2% 3.9M
|
Non-Energy Minerals
|
| O: -2.34%
H: 4.04%
C: 4.04%
approval corporation
Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes
Published: 2022-03-28 (Crawled : 22:00) - globenewswire.com
NVO | $123.9 -0.49% 0.23% 2.9M
|
Health Technology
|
| O: 2.86%
H: 0.47%
C: -0.72%
ozempic treatment diabetes
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
Published: 2022-03-28 (Crawled : 21:00) - prnewswire.com
NBIX | $131.68 -2.21% -2.26% 770K
|
Health Technology
|
| O: 0.16%
H: 0.51%
C: -0.94%
dysval treatment approval
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
treatment dupixent children
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
Published: 2022-03-28 (Crawled : 16:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: -1.22%
takhzyro hereditary angioedema
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia
Published: 2022-03-28 (Crawled : 12:20) - biospace.com/
MITO | $0.32 0.25%
|
Health Technology
|
| O: 2.92%
H: 2.95%
C: -3.91%
treatment fda drug elamipretide friedreich's ataxia designation friedreich’s ataxia
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses
Published: 2022-03-28 (Crawled : 11:00) - biospace.com/
STAA | $46.22 -7.17% -7.72% 740K
|
Health Technology
|
| O: 14.98%
H: 3.86%
C: -3.78%
visian fda approval
Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
Published: 2022-03-28 (Crawled : 11:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
xenpozyme therapy
Jyseleca® approved in Japan for ulcerative colitis
Published: 2022-03-28 (Crawled : 08:00) - biospace.com/
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: 0.07%
H: 0.7%
C: 0.39%
GLPG | $29.845 -1.34% -1.36% 150K
|
Health Technology
|
| O: 1.83%
H: 1.42%
C: -1.11%
jyseleca ulcerative colitis
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.